"What" Series

What is the IIT research in clinical trials？

5 December 2023
2 min read

Investigator-initiated trials (IITs) are established and managed by non-pharmaceutical researchers, such as clinicians and researchers working in a health institution. Most IITs are designed to support the development of new clinical practice guidelines or compare the effectiveness of existing treatments.

Keep Reading
Back to all blogs →
Decoding HS-10365: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
Clinical Progress
4 min read
Decoding HS-10365: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
1 December 2023
The 2023 AACR Congress set the scene with the revelation of the latest clinical outcomes of HS-10365, a highly potent and selective RET TKI, offering significant insights into its potential therapeutic benefits.
Read →
Abeona Therapeutics Reveals FDA Approval and Priority Review Provision for Pz-cel Biologics License Application (BLA)
Latest Hotspot
3 min read
Abeona Therapeutics Reveals FDA Approval and Priority Review Provision for Pz-cel Biologics License Application (BLA)
1 December 2023
Abeona Therapeutics Inc. confirms FDA priority review for their therapy, pz-cel (prademagene zamikeracel), Biologics License Application.
Read →
What are FLT3 inhibitors and how do you quickly get the latest development progress?
Valuable Targets
5 min read
What are FLT3 inhibitors and how do you quickly get the latest development progress?
1 December 2023
FLT3 inhibitors are drugs that competitively inhibit the ATP binding site in the FLT3 receptor, leading to cell cycle arrest and differentiation.
Read →
Cadonilimab, a PD-1/CTLA-4 bispecific antibody, met its primary endpoint by halting progression in a Phase III recurrent/metastatic cervical cancer trial
Latest Hotspot
3 min read
Cadonilimab, a PD-1/CTLA-4 bispecific antibody, met its primary endpoint by halting progression in a Phase III recurrent/metastatic cervical cancer trial
1 December 2023
In the Phase III trial for the initial treatment of recurrent/metastatic cervical cancer in all types of patients, Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) has achieved the primary goal of halting disease progression.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.